<status value="active"/> <author> <name value="Computable Publishing®: MEDLINE-to-FEvIR Converter"/> </author> <publisher value="Computable Publishing LLC"/> <contact> <telecom> <system value="email"/> <value value="support@computablepublishing.com"/> </telecom> </contact> <description value="This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."/> <useContext> <code> <system value="http://terminology.hl7.org/CodeSystem/citation-classification-type"/> <code value="fevir-platform-use"/> <display value="FEvIR Platform Use"/> </code> <valueCodeableConcept> <coding> <system value="http://terminology.hl7.org/CodeSystem/citation-artifact-classifier"/> <code value="medline-base"/> <display value="Medline Base"/> <userSelected value="false"/> </coding> </valueCodeableConcept> </useContext> <copyright value="Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse)."/> <approvalDate value="2008-12-16"/> <lastReviewDate value="2025-05-29"/> <classification> <type> <coding> <system value="http://terminology.hl7.org/CodeSystem/citation-classification-type"/> <code value="citation-source"/> <display value="Citation Source"/> </coding> </type> <classifier> <text value="MEDLINE"/> </classifier> </classification> <classification> <type> <coding> <system value="http://terminology.hl7.org/CodeSystem/citation-classification-type"/> <code value="medline-owner"/> <display value="MEDLINE Citation Owner"/> </coding> </type> <classifier> <coding> <system value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value"/> <code value="NLM"/> <display value="National Library of Medicine, Index Section"/> <userSelected value="false"/> </coding> </classifier> </classification> <currentState> <coding> <system value="http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type"/> <code value="medline-medline"/> <display value="Medline Citation Status of Medline"/> </coding> </currentState> <currentState> <coding> <system value="http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type"/> <code value="pubmed-publication-status-ppublish"/> <display value="PubMed PublicationStatus of ppublish"/> </coding> </currentState> <statusDate> <activity> <coding> <system value="http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type"/> <code value="pubmed-pubstatus-received"/> <display value="PubMed Pubstatus of Received"/> </coding> </activity> <period> <end value="2007-11-22"/> </period> </statusDate> <statusDate> <activity> <coding> <system value="http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type"/> <code value="pubmed-pubstatus-revised"/> <display value="PubMed Pubstatus of Revised"/> </coding> </activity> <period> <end value="2008-04-08"/> </period> </statusDate> <statusDate> <activity> <coding> <system value="http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type"/> <code value="pubmed-pubstatus-accepted"/> <display value="PubMed Pubstatus of Accepted"/> </coding> </activity> <period> <end value="2008-04-09"/> </period> </statusDate> <statusDate> <activity> <coding> <system value="http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type"/> <code value="pubmed-pubstatus-pubmed"/> <display value="PubMed Pubstatus of Pubmed"/> </coding> </activity> <period> <end value="2008-05-30T09:00:00.000Z"/> </period> </statusDate> <statusDate> <activity> <coding> <system value="http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type"/> <code value="pubmed-pubstatus-medline"/> <display value="PubMed Pubstatus of Medline"/> </coding> </activity> <period> <end value="2008-12-17T09:00:00.000Z"/> </period> </statusDate> <statusDate> <activity> <coding> <system value="http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type"/> <code value="pubmed-pubstatus-entrez"/> <display value="PubMed Pubstatus of Entrez"/> </coding> </activity> <period> <end value="2008-05-30T09:00:00.000Z"/> </period> </statusDate> <statusDate> <activity> <coding> <system value="http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type"/> <code value="pubmed-pubstatus-pmc-release"/> <display value="PubMed Pubstatus of PMC release"/> </coding> </activity> <period> <end value="2009-09-01"/> </period> </statusDate> <citedArtifact> <identifier> <system value="https://pubmed.ncbi.nlm.nih.gov"/> <value value="18508207"/> </identifier> <identifier> <type> <coding> <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/> <code value="ACSN"/> <display value="Accession ID"/> </coding> <text value="mid"/> </type> <value value="NIHMS61453"/> </identifier> <identifier> <system value="https://www.ncbi.nlm.nih.gov/pmc/"/> <value value="PMC2613766"/> </identifier> <identifier> <system value="https://doi.org"/> <value value="10.1016/j.drugalcdep.2008.04.002"/> </identifier> <identifier> <type> <coding> <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/> <code value="ACSN"/> <display value="Accession ID"/> </coding> <text value="pii"/> </type> <value value="S0376-8716(08)00140-3"/> </identifier> <title> <type> <coding> <system value="http://hl7.org/fhir/title-type"/> <code value="primary"/> <display value="Primary title"/> </coding> </type> <language value="en"/> <text value="A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal."/>

Generated Narrative: PublicationRecord 179637

version: 25; Last updated: 2026-06-26 20:07:22+0000

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/PublicationRecord/179637

identifier: FEvIR Object Identifier/179637, https://pubmed.ncbi.nlm.nih.gov/18508207

title: 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

status: Active

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

Citation Classification Type: fevir-platform-use (FEvIR Platform Use)

Medline Base

copyright:

Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).

approvalDate: 2008-12-16

lastReviewDate: 2025-05-29

classification
type: Citation Source
classifier: MEDLINE

classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate
activity: PubMed Pubstatus of Received
period: ?? --> 2007-11-22

statusDate
activity: PubMed Pubstatus of Revised
period: ?? --> 2008-04-08

statusDate
activity: PubMed Pubstatus of Accepted
period: ?? --> 2008-04-09

statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2008-05-30 09:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2008-12-17 09:00:00+0000

statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2008-05-30 09:00:00+0000

statusDate
activity: PubMed Pubstatus of PMC release
period: ?? --> 2009-09-01

citedArtifact
identifier: https://pubmed.ncbi.nlm.nih.gov/18508207, mid/NIHMS61453, https://www.ncbi.nlm.nih.gov/pmc//PMC2613766, https://doi.org/10.1016/j.drugalcdep.2008.04.002, pii/S0376-8716(08)00140-3
Titles
- Type Language Text
* Primary title English
A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Abstracts
- Type Text
* Primary human use
CONTEXT: Lofexidine is an alpha-2-adrenergic receptor agonist that is approved in the United Kingdom for the treatment of opioid withdrawal symptoms. Lofexidine has been reported to have more significant effects on decreasing opioid withdrawal symptoms with less hypotension than clonidine. OBJECTIVE: To demonstrate that lofexidine is well tolerated and effective in the alleviation of observationally defined opioid withdrawal symptoms in opioid dependent individuals undergoing medically supervised opioid detoxification as compared to placebo. DESIGN: An inpatient, Phase 3, placebo-controlled, double-blind, randomized multi-site trial with three phases: (1) opioid agonist stabilization phase (days 1-3), (2) detoxification/medication or placebo phase (days 4-8), and (3) post detoxification/medication phase (days 9-11). SUBJECTS: Sixty-eight opioid dependent subjects were enrolled at three sites with 35 randomized to lofexidine and 33 to placebo. MAIN OUTCOME MEASURE: Modified Himmelsbach Opiate Withdrawal Scale (MHOWS) on study day 5 (second opioid detoxification treatment day). RESULTS: Due to significant findings, the study was terminated early. On the study day 5 MHOWS, subjects treated with lofexidine had significantly lower scores (equating to fewer/less severe withdrawal symptoms) than placebo subjects (least squares means 19.5+/-2.1 versus 30.9+/-2.7; p=0.0019). Lofexidine subjects had significantly better retention in treatment than placebo subjects (38.2% versus 15.2%; Log rank test p=0.01). CONCLUSIONS: Lofexidine is well tolerated and more efficacious than placebo for reducing opioid withdrawal symptoms in inpatients undergoing medically supervised opioid detoxification.

relatesTo
type: Cites
classifier: Journal Article
citation:
Aghajanian GK. Central noradrenergic neurons: a locus for the functional interplay between alpha-2 adrenoceptors and opiate receptors. J Clin Psychiatry. 1982;43(6 Pt 2):20–24.

target: https://pubmed.ncbi.nlm.nih.gov/6282816/
relatesTo
type: Cites
classifier: Journal Article
citation:
Aghajanian GK. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature. 1978;276(5684):186–188.

target: https://pubmed.ncbi.nlm.nih.gov/216919/
relatesTo
type: Cites
classifier: Journal Article
citation:
Aigner A, Schmidt U. Lofexidine, a new, antihypertensive imidazoline derivative. Clinical profile of action with single-drug treatment and in combination with hydrochlorothiazide. Arzneimittelforschung. 1982;32(8a):976–983.

target: https://pubmed.ncbi.nlm.nih.gov/6890373/
relatesTo
type: Cites
classifier: Journal Article
citation:
Akhurst JS. The use of lofexidine by drug dependency units in the United Kingdom. Eur Addict Res. 1999;5(1):43–49.

target: https://pubmed.ncbi.nlm.nih.gov/10085500/
relatesTo
type: Cites
classifier: Journal Article
citation:
Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J. Neurosci. 1998;8(11):4287–4298.

target: https://pubmed.ncbi.nlm.nih.gov/2903226/
relatesTo
type: Cites
classifier: Journal Article
citation:
Aston-Jones G, Hirata H, Akaoka H. Local opiate withdrawal in locus coeruleus in vivo. Brain Res. 1997;765(2):331–336.

target: https://pubmed.ncbi.nlm.nih.gov/9313908/
relatesTo
type: Cites
classifier: Journal Article
citation:
Bearn J, Gossop M, Strang J. Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1996;43(1–2):87–91.

target: https://pubmed.ncbi.nlm.nih.gov/8957147/
relatesTo
type: Cites
classifier: Journal Article
citation:
Bearn J, Gossop M, Strang J. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend. 1998;50:227–232.

target: https://pubmed.ncbi.nlm.nih.gov/9649976/
relatesTo
type: Cites
classifier: Journal Article
citation:
Buccafusco JJ, Marshall DC. Dorsal root lesions block the expression of morphine withdrawal elicited from the rat spinal cord. Neurosci Lett. 1985;59(3):319–324.

target: https://pubmed.ncbi.nlm.nih.gov/4058799/
relatesTo
type: Cites
classifier: Journal Article
citation:
Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1998;50(3):251–254.

target: https://pubmed.ncbi.nlm.nih.gov/9649979/
relatesTo
type: Cites
classifier: Journal Article
citation:
Freedman JE, Aghajanian GK. Opiate and alpha 2-adrenoceptor responses of rat amygdaloid neurons: co-localization and interactions during withdrawal. J Neurosci. 1985;5(11):3016–3024.

target: https://pubmed.ncbi.nlm.nih.gov/2997411/
relatesTo
type: Cites
classifier: Journal Article
citation:
Gold MS, Pottash AC, Sweeney DR, Extein I, Annitto WJ. Opiate detoxification with lofexidine. Drug Alcohol Depend. 1981;8(4):307–315.

target: https://pubmed.ncbi.nlm.nih.gov/7338185/
relatesTo
type: Cites
classifier: Journal Article
citation:
Gonzalez G, Oliveto A, Kosten TR. Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother. 2004;5(4):713–725.

target: https://pubmed.ncbi.nlm.nih.gov/15102558/
relatesTo
type: Cites
classifier: Journal Article
citation:
Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend. 1988;21(3):253–259.

target: https://pubmed.ncbi.nlm.nih.gov/3048954/
relatesTo
type: Cites
classifier: Journal Article
citation:
Gossop M. The development of a short opiate withdrawal scale. Addict Behav. 1990;15(5):487–490.

target: https://pubmed.ncbi.nlm.nih.gov/2248123/
relatesTo
type: Cites
classifier: Journal Article
citation:
Gowing LR, Farrell M, Ali RL, White JM. Alpha 2-adrenergic agonists in opioid withdrawal. Addiction. 2002;97(1):49–58.

target: https://pubmed.ncbi.nlm.nih.gov/11895270/
relatesTo
type: Cites
classifier: Journal Article
citation:
Gowing L, Farrell M, Ali R, White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews CD002024. 2004

target: https://pubmed.ncbi.nlm.nih.gov/15495025/
relatesTo
type: Cites
classifier: Journal Article
citation:
Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293–308.

target: https://pubmed.ncbi.nlm.nih.gov/3687892/
relatesTo
type: Cites
classifier: Journal Article
citation:
Herman BH, Vocci F, Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal: medication development issues for opiate addiction. Neuropsychopharmacology. 1995;13:269–294.

target: https://pubmed.ncbi.nlm.nih.gov/8747752/
relatesTo
type: Cites
citation:
Herman BH, O'Brien CP. Clinical medications development for opiate addiction: Focus on nonopioids and opioid antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention. Seminars in Neuroscience. 1997;9:158–172.

relatesTo
type: Cites
classifier: Journal Article
citation:
Howells C, Allen S, Gupta J, Stillwell G, Marsden J, Farrell M. Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug Alcohol Depend. 2002;67(2):169–176.

target: https://pubmed.ncbi.nlm.nih.gov/12095666/
relatesTo
type: Cites
classifier: Journal Article
citation:
Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58(5):503–508.

target: https://pubmed.ncbi.nlm.nih.gov/11343531/
relatesTo
type: Cites
classifier: Journal Article
citation:
Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43(3):289–294.

target: https://pubmed.ncbi.nlm.nih.gov/3954551/
relatesTo
type: Cites
classifier: Journal Article
citation:
Jarrott B, Louis WJ, Summers RJ. Characterization of central alpha-adrenoceptors using 3H-clonidine and its derivatives. Chest. 1983;83 Suppl 2:S339–S340.

target: https://pubmed.ncbi.nlm.nih.gov/6129948/
relatesTo
type: Cites
citation:
Jasinski DR. Assessment of the abuse potentiality of morphine-like drugs (methods used in man) In: Martin WR, editor. Handbook of Experimental Pharmacology. Vol 45. Berlin: Springer-Verlag; 1977. pp. 197–258.

relatesTo
type: Cites
classifier: Journal Article
citation:
Kahn A, Mumford JP, Rogers GA, Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend. 1997;44(1):57–61.

target: https://pubmed.ncbi.nlm.nih.gov/9031821/
relatesTo
type: Cites
citation:
Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, Inc.; 1980.

relatesTo
type: Cites
classifier: Journal Article
citation:
Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Gaspari J, Hogan I, O'Connor C. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry. 1985;42(4):391–394.

target: https://pubmed.ncbi.nlm.nih.gov/3977557/
relatesTo
type: Cites
citation:
Kolb MR, Himmelsbach CK. Clinical studies of drug addiction. III. A critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Amer. J. Psychiatry. 1938;94:759–797.

relatesTo
type: Cites
classifier: Journal Article
citation:
Lin SK, Strang J, Su LW, Tsai CJ, Hu WH. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend. 1997;48(2):127–133.

target: https://pubmed.ncbi.nlm.nih.gov/9363412/
relatesTo
type: Cites
classifier: Journal Article
citation:
Marjamaki A, Luomala K, Ala-Uotila S, Scheinen M. Use of recombinant human alpha 2-adrenoceptors to characterize subtype selectively of antagonist binding. Eur J Pharmacol. 1993;246(3):219–226.

target: https://pubmed.ncbi.nlm.nih.gov/7901041/
relatesTo
type: Cites
classifier: Journal Article
citation:
National Survey on Drug Use and Health. 2006. [accessed on April 10, 2008]. Availabel at: http://www.oas.samhsa.gov/nsduh/2k6nsduh/2k6Results.cfm.

target: https://pubmed.ncbi.nlm.nih.gov/24288193/
relatesTo
type: Cites
classifier: Journal Article
citation:
O’Brien PC, Fleming TR. A multiple testing procedure for clinical trails. Biometrics. 1979;35(3):549–556.

target: https://pubmed.ncbi.nlm.nih.gov/497341/
relatesTo
type: Cites
citation:
Office of National Drug Control Policy. Heroin Fact Sheet. 2003. [Accessed February 6, 2006]. Available at: http://www.whitehousedrugpolicy.gov/publications/factsht/heroin/index.html.

relatesTo
type: Cites
classifier: Journal Article
citation:
Preston KL, Bigelow GE. Pharmacological advances in addiction treatment. Int J Addict. 1985;20(6–7):845–867.

target: https://pubmed.ncbi.nlm.nih.gov/2867050/
relatesTo
type: Cites
classifier: Journal Article
citation:
Raistrick D, West D, Finnegan O, Thistlethwaite G, Brearley R, Banbery J. A comparison of buprenorphine annd lofexidine for community opiate detoxification: results from a randomized controlled trail. Addict. 2005;100(12):1860–1867.

target: https://pubmed.ncbi.nlm.nih.gov/16367987/
relatesTo
type: Cites
classifier: Journal Article
citation:
Shearman GT, Lal H, Ursillo RC. Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat. Pharmacol Biochem Behav. 1980;12(4):573–575.

target: https://pubmed.ncbi.nlm.nih.gov/7190295/
relatesTo
type: Cites
citation:
Snedecor GW, Cochran WG. Statistical Methods. Ames, IA: Iowa State University Press; 1967.

relatesTo
type: Cites
citation:
Substance Abuse and Mental Health Data Archive. National Household Survey on Drug Abuse (NHSDA) series. 2003. [Accessed February 6, 2006]. Available at http://www.icpsr.umich.edu/SAMHDA/ and http://webapp.icpsr.umich.edu/cocoon/SAMHDA-SERIES/00064.xml.

relatesTo
type: Cites
classifier: Journal Article
citation:
Uhlen S, Wikberg JE. Delineation of three pharmacological subtypes of alpha 2-adrenoceptor in the rat kidney. Br J Pharmacol. 1991;104(3):657–6419.

target: https://pubmed.ncbi.nlm.nih.gov/1665747/
relatesTo
type: Cites
citation:
Vocci FJ. Opiates and addiction. In: Sibley DR, Hanin I, Kuhar M, Skolnick P, editors. Handbook of Contemporary Neuropharmacology Volume 2. John Wiley and Sons publisher; 2007. pp. 691–705.

relatesTo
type: Cites
classifier: Journal Article
citation:
Washton AM, Resnick RB, Perzel JF, Garwood J. Opiate detoxification using lofexidine. NIDA Res Monogr. 1982;41:261–263.

target: https://pubmed.ncbi.nlm.nih.gov/6811916/
relatesTo
type: Cites
classifier: Journal Article
citation:
White R, Alcorn R, Feinmann C. Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine. Drug Alcohol Depend. 2001;65(1):77–83.

target: https://pubmed.ncbi.nlm.nih.gov/11714592/
relatesTo
type: Cites
citation:
Yu E, Herman BH, Miotto K, Montgomery A, Fudala PJ, Chiang CN, Fisher C, Kampman K, Dhopesh V, Cornish J, Walsh B, Davies K, Vocci F, Bridge P, Ling W, O’Brien CP. NIDA Research Monograph. Rockville: DHHS/NIH/NIDA; 1999. In-patient safety evaluation of lofexidine (alpha-2 adrenergic agonist) for opiate withdrawal; p. 227.

relatesTo
type: Cites
citation:
Yu E, Herman BH, Miotto K, Montgomery A, Fudala PJ, Chiang CN, Fisher C, Kampman K, Dhopesh V, Cornish J, Walsh B, Davies K, Vocci F, Bridge P, Ling W, O’Brien CP. In-patient safety evaluation of lofexidine (alpha-2 adrenergic agonist) for opiate detoxification. Drug Alcohol Depend. 2001;63:S175.

publicationForm
publishedIn
type: Periodical
identifier: Print ISSN Type/0376-8716, ISOAbbreviation/Drug Alcohol Depend, ISSN Linking/0376-8716, Medline Title Abbreviation/Drug Alcohol Depend, NLM Unique ID/7513587
title: Drug and alcohol dependence
publisherLocation: Ireland
citedMedium: Print
volume: 97
issue: 1-2
articleDate: 2008-09-01
publicationDateText: 2008-Sep-01
pageString: 158-68
publicationForm
citedMedium: Internet without issue
articleDate: 2008-05-27
webLocation
classifier: Abstract
url: https://pubmed.ncbi.nlm.nih.gov/18508207/
webLocation
classifier: DOI Based
url: https://doi.org/10.1016/j.drugalcdep.2008.04.002
classification
type: Publishing Model
classifier: Print Electronic
classification
type: Chemical
classifier: Adrenergic alpha-Agonists, Analgesics, Opioid, Clonidine, lofexidine
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Yu E
forenameInitials: E
affiliation: University of Pennsylvania & Philadelphia Veterans Affairs Medical Center, Philadelphia VAMC 116, University & Woodland Avenues, Philadelphia, PA 19104, USA. yu_e@mail.trc.upenn.edu <yu_e@mail.trc.upenn.edu>
entry
contributor: Miotto K
forenameInitials: K
entry
contributor: Akerele E
forenameInitials: E
entry
contributor: Montgomery A
forenameInitials: A
entry
contributor: Elkashef A
forenameInitials: A
entry
contributor: Walsh R
forenameInitials: R
entry
contributor: Montoya I
forenameInitials: I
entry
contributor: Fischman MW
forenameInitials: MW
entry
contributor: Collins J
forenameInitials: J
entry
contributor: McSherry F
forenameInitials: F
entry
contributor: Boardman K
forenameInitials: K
entry
contributor: Davies DK
forenameInitials: DK
entry
contributor: O'Brien CP
forenameInitials: CP
entry
contributor: Ling W
forenameInitials: W
entry
contributor: Kleber H
forenameInitials: H
entry
contributor: Herman BH
forenameInitials: BH

Generated Narrative: Practitioner #contributor0

name: Elmer Yu

Generated Narrative: Practitioner #contributor1

name: Karen Miotto

Generated Narrative: Practitioner #contributor2

name: Evaristo Akerele

Generated Narrative: Practitioner #contributor3

name: Ann Montgomery

Generated Narrative: Practitioner #contributor4

name: Ahmed Elkashef

Generated Narrative: Practitioner #contributor5

name: Robert Walsh

Generated Narrative: Practitioner #contributor6

name: Ivan Montoya

Generated Narrative: Practitioner #contributor7

name: Marian W Fischman

Generated Narrative: Practitioner #contributor8

name: Joseph Collins

Generated Narrative: Practitioner #contributor9

name: Frances McSherry

Generated Narrative: Practitioner #contributor10

name: Kathy Boardman

Generated Narrative: Practitioner #contributor11

name: David K Davies

Generated Narrative: Practitioner #contributor12

name: Charles P O'Brien

Generated Narrative: Practitioner #contributor13

name: Walter Ling

Generated Narrative: Practitioner #contributor14

name: Herbert Kleber

Generated Narrative: Practitioner #contributor15

name: Barbara H Herman

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: PublicationRecord 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
content
type: components (if present) include qualifier codings
classifier: Adrenergic alpha-Agonists
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: adverse effects
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Adult
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Analgesics, Opioid
freeToShare: true
Components
- Type Classifier
* qualifier is Major topic
content
type: components (if present) include qualifier codings
classifier: Clonidine
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: adverse effects
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: analogs & derivatives
Components
- Type Classifier
* is Major topic Yes
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Data Collection
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Double-Blind Method
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Female
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Psychiatric Status Rating Scales
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Substance Abuse Detection
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Substance Withdrawal Syndrome
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Survival Analysis
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Treatment Outcome
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic